Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities. - Wikidata - awgldk - TriplyDB

Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities.

Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities.

http://www.wikidata.org/entity/Q36136786

about

Advanced health biotechnologies in Thailand: redefining policy directions Economic evaluations of personalized medicine: existing challenges and current developments Pharmacogenetics and anaesthesia: the value of genetic profiling Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development Landscape of next-generation sequencing technologies.Designing a randomized clinical trial to evaluate personalized medicine: a new approach based on risk prediction.Parents' attitudes toward pediatric genetic testing for common disease risk.Health technology assessment and private payers' coverage of personalized medicine.Genomic testing to determine drug response: measuring preferences of the public and patients using Discrete Choice Experiment (DCE).Personalized medicine: new genomics, old lessons Economic analyses of genetic tests in personalized medicine: clinical utility first, then cost utility.Getting our priorities straight: a novel framework for stakeholder-informed prioritization of cancer genomics research.Personalizing medicine with clinical pharmacogenetics Differences in Weight Loss Between Persons on Standard Balanced vs Nutrigenetic Diets in a Randomized Controlled Trial.A CTSA agenda to advance methods for comparative effectiveness research.Value of research analysis: an application to drug development Was it worth it? Patients' perspectives on the perceived value of genomic-based individualized medicine.Economic Evaluation in Stratified Medicine: Methodological Issues and Challenges Assessing personalized medicines in Australia: a national framework for reviewing codependent technologies.Issues surrounding the health economic evaluation of genomic technologies.Characteristics associated with informed consent for genetic studies in the ACCORD trial.Storing and interpreting genomic information in widely deployed electronic health record systems.Application of genotype-guided cancer therapy in solid tumors.Is individualized medicine more cost-effective? A systematic review.Dashboard systems: implementing pharmacometrics from bench to bedside.Dashboard systems: Pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodies.Economic Evaluations of Pharmacogenetic Approaches in Infectious Diseases: A Review of Current Approaches and Evaluation of Critical Aspects Affecting their Quality.The Routine Clinical use of Pharmacogenetic Tests: What it Will Require?Multiomics medicine in oncology: assessing effectiveness, cost-effectiveness and future research priorities for the molecularly unique individual.Personalised medicine: a critique on the future of health care.Personalized medicine and comparative effectiveness research in an era of fixed budgets.A risk-benefit analysis of factor V Leiden testing to improve pregnancy outcomes: a case study of the capabilities of decision modeling in genomics.Challenges in the codevelopment of companion diagnostics.Pharmacogenomics Aspect of Warfarin Therapy Personalized medicine and genome-based treatments: Why personalized medicine ≠ individualized treatments Are health technology assessments of pharmacogenetic tests feasible? A case study ofCYP2D6testing in the treatment of breast cancer with tamoxifen

P2860

Q21245493-C833FECE-3473-49FB-99D7-CC499FC0DEA4 Q26797183-151BC705-C3E8-4742-AB4C-2697C82A9875 Q26859221-ECDA6232-86D2-4B50-8F3E-0AAFB35B3CFF Q29013931-354AF77A-2D4E-4B71-BC48-D4D3488810EA Q34187217-A4DA885A-C335-43DC-98DD-74588AC1013E Q34366871-9D96FEE1-6813-449F-89F3-0E2005403DF9 Q34839203-2CB51D93-EB58-42D4-8E56-A4FC408150B6 Q34974174-14D65EF3-D227-4111-A4C6-E7B29C83C5C8 Q35029538-9DA538FF-1DFB-4E26-A097-BD7161A6545F Q35082635-92904941-46C0-4F4E-9811-AC986B2AD2A8 Q35681121-6784B365-93AB-4520-B0C6-1651221D532A Q35775766-1C54E43F-2FFA-48EB-9639-11CC03D5FA5F Q35791989-40B459BB-4E3B-4B11-A03C-42A4A0077A23 Q35988480-D16EC465-FADF-47FE-A169-8D24BB797DDD Q36054222-99F7B02A-D489-4185-BB26-111162009633 Q36136744-10F025C6-4838-4C49-811F-4BF736ED41E0 Q36698414-14CBC3F9-33B8-4A51-AAF6-AB531DF48742 Q36883280-BDEFD911-1F3F-4A94-B693-1875A7FC97CE Q37133974-C0FBF463-7D7E-41E3-8138-5226DC5690B2 Q37541151-66675FDC-7EDE-4C9E-8981-4A278A38B5A2 Q37571916-093E7A59-358A-42B8-826B-6F2EE69912D5 Q38129303-5DCB25EA-7ED9-46AA-9C9D-16A9C8AE687A Q38170457-1A8EF195-E445-4F14-B0CD-2522A971FC4F Q38191496-8F9AFE18-B034-4F35-803F-B1C065533B55 Q38221759-5D0255E6-570D-486E-A1B3-5C93D31C0201 Q38364464-3D5770A2-7661-4F42-8CFD-D5FC5744277C Q38904691-CC32F813-F3E7-4379-8A7E-D9A47171281A Q39150032-FD1A1932-2A71-4A19-B31D-BE02F7B28148 Q39352133-5AA649C0-1974-4286-9BBA-1183A516D6DE Q39447700-DCE7072C-0E97-44CB-9D75-7DA3B9F77A73 Q42250319-DFEB9F9B-4E7E-46B7-99BD-B71234EF3A3F Q46321924-28F923D3-FDA2-4B49-B60B-EFABA1889E3B Q53870892-44B25968-2DB5-462E-B03A-4A0B70860170 Q57179825-793353D9-5248-4768-8099-F609B4DC67AD Q57519272-C4B0CA14-1C08-48DE-A0C9-99003A31EA9F Q57697028-7C087BCD-EDC4-4B4F-B8D3-66C27D2E5754

P2860

Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities.

http://www.wikidata.org/entity/Q36136786

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Personalized medicine and geno ...... nd future research priorities.

@ast

Personalized medicine and geno ...... nd future research priorities.

@en

type

label

Personalized medicine and geno ...... nd future research priorities.

@ast

Personalized medicine and geno ...... nd future research priorities.

@en

prefLabel

Personalized medicine and geno ...... nd future research priorities.

@ast

Personalized medicine and geno ...... nd future research priorities.

@en

P1433

Q36136786-3F28887C-DFFB-48E5-BDF0-29CBFA1D8DD5

P1476

Q36136786-8458B6FB-DE3C-455A-9B48-CCA5EF5FA920

P2093

Q36136786-11A71A43-4E22-4500-920E-7BB8417E0245

Q36136786-35E76243-111E-431B-8CF0-2BF8FC7CE1AC

Q36136786-5CE29B46-27B4-433C-9CFF-1E272D52A281

P2860

Q36136786-01F42388-8A12-4460-858C-0190D130784D

Q36136786-05967661-158E-466C-BA43-FA842ACF0319

Q36136786-06CCE7D4-30B8-4577-9F5F-98DF4951F731

Q36136786-0DDC681B-8F1A-4209-898E-30CC94A7F59C

Q36136786-16979FDB-40CC-4B01-A090-D712BA88CFEE

Q36136786-1C7E6519-8057-485B-B9C2-94FF08C87818

Q36136786-21695A37-A01B-4D28-ACD3-A7E28D4A513D

Q36136786-2A6981C1-47BE-4DFB-A20D-D3B8ABD643CF

Q36136786-2B1B2215-AA8E-4A67-BAB9-A5E2EE8EB3E4

Q36136786-30B54250-22F9-4421-83D7-8B2995673F9D

P304

Q36136786-120EB51C-F57F-495A-9A9C-368CC40E0F11

P31

Q36136786-9D5412B7-EC46-4D33-8B1A-AFAAB3212641

P356

Q36136786-0FDF3919-3A8C-4787-BE73-A322F52204E6

P433

Q36136786-6550D75D-6C15-4999-8457-AD5E989F7682

P478

Q36136786-324FE928-0140-4237-8D1B-448D743BA359

P50

Q36136786-4CD6B317-FB52-4189-9127-5DE367F7435C

Q36136786-CC02DE55-9A6B-44D2-87D0-D69210E7E759

P577

Q36136786-EA08B9A1-B194-4358-ACB8-E34EC84890B4

P698

Q36136786-1B840DCE-473B-4C57-A3C0-32D8001EDB30

P932

Q36136786-32E7F663-29CF-4BCB-ADC8-873D531D6DFF

P356

0272989X09347014

P1433

Medical Decision Making

P1476

Personalized medicine and geno ...... and future research priorities

@en

P2093

David L Veenstra

http://www.w3.org/2001/XMLSchema#string

Katrina Armstrong

http://www.w3.org/2001/XMLSchema#string

Lawrence J Lesko

http://www.w3.org/2001/XMLSchema#string

P2860

The path from genome-based research to population health: development of an international public health genomics network

Estimating the cost of new drug development: is it really 802 million dollars?

Estimation of the warfarin dose with clinical and pharmacogenetic data.

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

National surveillance of emergency department visits for outpatient adverse drug events.

Genetic determinants of response to warfarin during initial anticoagulation

Prioritizing future research on off-label prescribing: results of a quantitative evaluation

Personal utility and genomic information: look before you leap

Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force.

The impact of patient preferences on the cost-effectiveness of intensive glucose control in older patients with new-onset diabetes.

P304

328-340

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0272989X09347014

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-01-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20086232

http://www.w3.org/2001/XMLSchema#string

P932

4598076

http://www.w3.org/2001/XMLSchema#string